DanielEstebanGroszMD

Psychiatry • Encino, CA

Child & Adolescent Psychiatry, Psychopharmacology, Integrative Psychiatry

Medical Director, Eximia Clinical Research. Encino, California. Medical Director, Penny Lane Centers. North Hills, California.

Join to view full profile

Dr. Grosz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grosz's full profile

Already have an account?

Office
17777 Ventura Blvd
Suite 235
Encino, CA 91316
Phone+1 818-386-0500

Fax+1 818-386-2019

Summary

Diagnosis and Treatment of Mood Disorders, Anxiety Disorders and Attention Deficit Hyperactivity Disorder.

Research of Mood Disorders, Anxiety Disorders, ADHD, Eating Disorders, Migraines and Alzheimer’s Disease.

Education & Training

Montefiore Medical Center/Albert Einstein College of MedicineFellowship, Biological Psychiatry, 1988 - 1989
Montefiore Medical Center/Albert Einstein College of MedicineFellowship, Child and Adolescent Psychiatry, 1986 - 1988
University of Buenos AiresClass of 1977

Certifications & Licensure

CA State Medical License 1991 - 2025
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012

Clinical Trials

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
Terminated
Phase 3
Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease Start of enrollment: 2005 Apr 01
Unknown status
Phase 2
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
Completed
Phase 2
Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01
Completed
Phase 3
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Start of enrollment: 2014 Jul 07
Completed
Phase 2
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment Start of enrollment: 2014 Sep 01
Terminated
Not Applicable
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Start of enrollment: 2017 Mar 31
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

30 citations
Body mass index and response to antidepressants in depressed research subjects.
Nader Oskooilar, Charles S. Wilcox, My-Linh Tong, Daniel E. Grosz
The Journal of Clinical Psychiatry. 2009-11-15
53 citations
Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.
Egilius L.H. Spierings, Baltazar Gomez-Mancilla, Daniel E. Grosz, Clayton R. Rowland, Fredrick S. Whaley
Archives of Neurology. 2001-06-01
36 citations
Correlates of violence risk in hospitalized adolescents
Daniel Grosz, Deborah S. Lipschitz, Sofia Eldar, Graciela Finkelstein, Nigel Blackwood
Comprehensive Psychiatry. 1994-07-01

Research History

Medical DirectorPharmacology Research Institute Principal Investigator for more than 200 clinical trials1997 - 2023

Professional Memberships

American Academy of Child and Adolescent Psychiatry - AACAP
Member
American Society of Clinical Psychopharmacology
Member

Other Languages

Spanish